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INTRODUCTION
Stroke is a major cause of morbidity and mortality world-
wide. Although the past 50 yr have seen a decline in the in-
cidence of stroke in Western populations (1), the burden of
the disease in the Korean population has increased and is
expected to continue to rise with the increasing elderly pop-
ulation. The burden of stroke can be reduced if at-risk indi-
viduals are recognized and treated. Since only about two
thirds of ischemic strokes seem to be attributable to known
environmental risk factors (2), there are likely to be other as
yet unknown causal risk factors for ischemic stroke.
Several epidemiologic studies in families and in twins have
indicated a distinctive genetic component predisposing to
stroke (3). Identification of cerebral infarction susceptibility
genes might enhance prediction of disease risk. The comple-
tion of the Human Genome Project brought the promise of
genomic medicine, which is the use of whole-genome-derived
information to prevent, diagnose and treat complex polygenic
diseases such as stroke (4). One of the most significant ad-
vances in our understanding of the role of genetic factors in
the pathogenesis of stroke came from the deCODE Genet-
ics Group in Iceland, who reported the identification and
characterization of the phosphodiesterase 4D (PDE4D) gene,
which appears to confer an increased risk of ischemic stroke (5). 
However, recently published studies from different popu-
lations provide apparently conflicting evidence on the asso-
ciation between the PDE4D gene and ischemic stroke (6-
13). Furthermore, none of the previous studies clearly stated
whether subjects with silent cerebral infarction or asymp-
tomatic carotid atherosclerosis were appropriately excluded
from their control groups. In clinical practice, evidence of
silent infarction or asymptomatic carotid stenosis on mag-
netic resonance imaging (MRI) or MR angiography (MRA)
of the head is not uncommon in healthy-looking individu-
als (14, 15).
In the present study, the relationship between a represen-
tative PDE4D genotype and ischemic stroke was explored
in a case-control study of consecutive Korean patients with
ischemic stroke and healthy controls who were neurological-
ly and radiologically proven to be stroke-free. To our knowl-
edge, this is the first report concerning the association of the
PDE4D gene with ischemic stroke in a Korean population.
MATERIALS AND METHODS
Subjects
Consecutive first-ever ischemic stroke patients admitted
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Phosphodiesterase 4D Gene and Risk of Noncardiogenic Ischemic
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Recently published studies from different populations provide apparently conflicting
evidence on the association between the phosphodiesterase 4D (PDE4D) gene
and ischemic stroke. The relationship between a representative PDE4D genotype
and ischemic stroke was explored in a case-control study of 205 consecutive Korean
patients with noncardiogenic ischemic stroke and 103 healthy controls who were
neurologically and radiologically proven to be stroke-free. We selected and geno-
typed a PDE4D single nucleotide polymorphism (SNP 41, rs152312) as a candi-
date marker for susceptibility to ischemic stroke because SNP 41 has shown the
most significant association with stroke in both a meta-analysis and the original Ice-
landic study of the PDE4D gene. No significant difference was observed between
the cases and controls in the distribution of the PDE4D SNP 41 genotypes. The
results from the adjusted conditional logistic regression analysis (adjusted for age,
hypertension, diabetes and smoking status) showed no significant association bet-
ween PDE4D SNP 41 genotypes and an increased risk of noncardiogenic ischemic
stroke. The PDE4D gene is not a major risk factor for noncardiogenic ischemic
stroke in a Korean population, which supports the recent evidence suggesting that
the causative genetic variants of ischemic stroke may differ across populations.
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between January 2003 and December 2004 were approached
for consent to participate in this study. All patients under-
went MRI and MRA of the head within 48 hr after stroke
onset, and their strokes were classified according to the pre-
specified Trial of Org 10172 in Acute Stroke Treatment
(TOAST) criteria (16). In order to ensure homogeneity of
samples in terms of the underlying pathomechanism of stroke,
only patients with ischemic stroke classified as large artery
disease (LAD) or small vessel disease (SVD) were included
in the present study.
The control subjects were selected from patients who un-
derwent both MRI and MRA of the head for neurological
complaints other than stroke, primarily for headache. Pati-
ents having significant increased signal intensity lesions on
diffusion-weighted or fluid-attenuated inversion-recovery
MR images or vascular abnormalities on MRA of the head
were excluded from the study, as were patients with typical
vascular headaches.
Baseline demographic data (age, gender), history of con-
ventional vascular risk factors (hypertension, diabetes and
current smoker) and history of previous vascular events (myo-
cardial infarction, angina, claudication and peripheral vas-
cular disease) were obtained from each subject. 
Individuals with a proven cause of cardioembolism, such
as recent myocardial infarction, valvular heart disease, and
arrhythmia including atrial fibrillation, and those with a
history of previous peripheral vascular events were excluded
from the case and control groups.
The study was approved by the Institutional Review Board
of the hospital, and informed consent was obtained from all
study participants.
Marker selection and genotyping
We selected a PDE4D single nucleotide polymorphism
(SNP 41, rs152312) as a candidate marker for susceptibility
to ischemic stroke in a Korean population because SNP 41
has shown the most significant association with stroke in a
meta-analysis of nine case-control studies and in the origi-
nal Icelandic study (5, 17).
Genomic DNA was extracted from peripheral blood lym-
phocytes using a standard protocol. Polymerase chain reac-
tion (PCR) primers for PDE4D SNP 41 were designed based
on GenBank sequences (accession number: NM_006203,
AY245866): 5′ -ATACATGTGCCATGCTGGTG-3′ (for-
ward) and 5′ -CCTCCTAGGCTGGTGTGAAG-3′ (reverse).
PCR assays were carried out using 1.25 U of AmpliTaq Poly-
merase Gold (Applied Biosystems, CA, U.S.A.), 100 ng of
genomic DNA, 2.0-2.5 mM of MgCl2, and 10 μ M of primer.
The amplification conditions were as follows: an initial denat-
uration cycle at 95℃for 5 min, followed by 35 amplification
cycles (denaturation at 95℃ for 30 sec, annealing at 62℃
for 30 sec, and extension at 72℃for 1 min), and a final exten-
sion at 72℃for 7 min. The PCR products were electropho-
resed in a 1.2% agarose gel, and the amplified genomic DNA
fragments were extracted from the gel and purified using a
QIAquick
� gel extraction kit (Quiagen, Hilden, Germany)
according to the manufacturer’s instructions. Direct sequenc-
ing of both strands was performed using BigDye terminator
kits (PE Biosystems, CA, U.S.A.) to determine the individ-
ual genotypes.
Statistical analysis
The distribution of PDE4D SNP 41 among controls was
tested for Hardy-Weinberg equilibrium using an exact test.
Continuous and categorical variables were tested using a t
test and chi-square analysis. Single-marker associations bet-
ween phenotype and genotype were tested by chi-square anal-
ysis, and the relative risks for ischemic stroke associated with
each genotype were calculated by logistic regression analysis
(SPSS 14.OK for Windows; SPSS, Chicago, IL, U.S.A.). Dif-
ferences were considered significant for pvalues of ≤0.05.
RESULTS
The baseline characteristics of the cases and controls are
shown in Table 1. Compared with the controls, the cases were
significantly older and, as expected, had a higher prevalence
of conventional vascular risk factors at baseline. The cases con-
sisted of 113 patients with SVD and 92 patients with LAD.
The genotype frequencies for PDE4D SNP 41 were in Hardy-
Weinberg equilibrium in the control group (p=0.936)
Using a single-marker chi-square analysis, no significant
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Values are mean±SD or %.
Cases (n=205) Controls (n=103) p value
Age (yr) 64.8±11.6 61.8±10.4 0.025
Gender (female %) 47.3 54.4 0.18
Hypertension (%) 60.5 31.1 <0.001
Diabetes (%) 28.3 14.6 0.01
Smoking (%) 20 5.8 0.001
Table 1. Baseline characteristics of cases and controls
All results were expressed as number (% of total). p value for χ 2 test. 
SVD, small vessel disease; LAD, large artery disease.
Cases (n=205)




GG 48 (42.5) 41 (44.6) 89 (43.4) 52 (50.5)
GA 51 (45.1) 42 (45.7) 93 (45.4) 43 (41.7)
AA 14 (12.4) 9 (9.8) 23 (11.2) 8 (7.8)
p value 0.847 0.333
Table 2. Distribution of PDE4D SNP41 genotypesdifference was observed between SVD and LAD and between
the cases (SVD+LAD) and controls in the distribution of the
PDE4D SNP 41 genotypes (Table 2). The results from the
adjusted conditional logistic regression analysis (adjusted
for age, hypertension, diabetes and smoking status) showed
no significant association between the PDE4D SNP 41 geno-
types and an increased risk of noncardiogenic ischemic stroke
(Table 3).
DISCUSSION
A recent case-control study reported an association between
risk of ischemic stroke and genetic variation of the PDE4D
gene in an Icelandic population (5). However, there is a major
problem with combining individuals with cardiogenic and
carotid stroke into one subgroup for genetic analysis. Although
the authors insist that cardiogenic and carotid strokes are most
clearly related to atherosclerosis (5), only 25% of cardiogenic
strokes directly result from complications of coronary athe-
rosclerosis (18). Therefore, the combined subgroup is highly
heterogeneous in terms of the underlying pathomechanism
of stroke and therefore is not suitable for genetic analysis.
To avoid this problem in present study, only patients with
noncardiogenic ischemic stroke were selected as cases. 
The original Icelandic study reported that PDE4D SNP
41 was one of the variants most significantly associated with
ischemic stroke (5). Furthermore, a meta-analysis of nine
case-control studies consisting of 3,808 stroke cases and 4,377
controls also reported a significant association between stroke
and PDE4D SNP 41 (17). However, no association was found
between PDE4D SNP 41 and noncardiogenic ischemic stroke
in a Korean population in the present study. This result adds
to the growing body of recent evidence suggesting that vari-
ants in the PDE4D gene do not constitute a major risk fac-
tor for ischemic stroke (6, 7). The most likely explanation
for this discrepancy is that the genetic variants tested are not
causally associated with stroke, but rather are in linkage dis-
equilibrium with the causative alleles, which may differ across
populations. 
A Japanese group genotyped 35 genetic markers in STRK1,
a candidate locus for stroke identified in the original Icelandic
study (19), and found that two haplotype blocks were signif-
icantly associated with noncardiogenic ischemic stroke in a
Japanese population (9). Interestingly, one of the blocks was
located in the region of the PDE4D gene, including SNP 41,
but the other block, which was more significantly associat-
ed with noncardiogenic ischemic stroke, was located beyond
the region of the PDE4D gene in the STRK1 locus. The au-
thors of the Japanese study suggested that the region of the
PDE4D gene might be the susceptibility region for cardio-
embolic stroke and that the region identified in their study
might be the susceptibility region for noncardiogenic ische-
mic stroke (9). This suggestion is reinforced by a non-Ice-
landic European study in which a possible association bet-
ween the PDE4D gene and cardioembolic stroke, rather than
with ischemic stroke on the whole, was identified (6). Our
study also strengthens the Japanese scenario that there may
be a susceptibility region for noncardiogenic ischemic stroke
other than that of the PDE4D gene within the STRK1 locus.
Although the logic of their hypothesis concerning the sus-
ceptibility region for cardioembolic stroke is not clear, the
lesson from the Japanese study is obvious: the causative genet-
ic variants of ischemic stroke may differ across populations.
Further studies are needed to identify the causative genetic
variant in the PDE4D gene and to define the region of sus-
ceptibility for ischemic stroke in a Korean population. 
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